Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement